Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients - Université de Tours Accéder directement au contenu
Article Dans Une Revue British Journal of Clinical Pharmacology Année : 2017

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Soujanya Ratna Edupuganti
  • Fonction : Auteur
Julien Mélet
  • Fonction : Auteur

Résumé

Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients.

Dates et versions

hal-02425330 , version 1 (30-12-2019)

Identifiants

Citer

Bertrand Lioger, Soujanya Ratna Edupuganti, Denis Mulleman, Christophe Passot, Celine Desvignes, et al.. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. British Journal of Clinical Pharmacology, 2017, 83 (8), pp.1773-1781. ⟨10.1111/bcp.13270⟩. ⟨hal-02425330⟩
31 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More